Polonsky W, Gamble C, Iyer N, Martin M, Hamersky C (May 2021) Exploring why people with type 2 diabetes do or do not persist with Glucagon-Like Peptide-1 receptor agonist therapy: a qualitative study
Key takeaways Cleveland Clinic real-world data presented at ASCO 2026 found patients who started a GLP-1 receptor agonist (semaglutide or tirzepatide) after a breast cancer diagnosis were about 43% less likely to progress to Stage IV disease than patients who started a DPP-4 inhibitor (hazard ratio 0.57, 95% CI 0.46 to 0.71
Brompheniramine used in cough syrups
Oral Wegovy (Semaglutide Pill) Offering a flexible daily oral option, Oral Wegovy allows patients to experience weight management benefits without injections
What lifestyle changes should accompany the use of Ozempic and Wegovy
When combined with the proper diet and physical activity B12 shots can help enhance weight loss efforts and boost energy levels